About
Background
KaMoZo Biologics, LLC is a biotechnology company founded in 2025 in Nashville, Tennessee. It was formed to develop and commercialize a novel intracellular cancer therapy and a method for rapid intracellular drug delivery. These technologies were invented by KaMoZo’s founder, Jozef Zienkiewicz, Ph.D., during his decades-long research career.
In collaboration with Tennessee universities, we aim to validate and commercialize our therapies to create an effective cancer treatment. We are particularly focused on treating types of cancer that lack specific antibody therapies, such as triple negative breast, pancreatic, colon, and prostate cancers. We also aim to advance the field of intracellular drug delivery for biologic and synthetic therapeutics such as gene, protein, peptide, or RNA vaccines.
Pipeline
| nuclear import inhibitors | species-specific cell penetrating peptides for rapid intracellular drug delivery | ||
| in human medicine | in veterinary medicine | ||
| # of sequences identified in in silico study | 1,095 | 2,685 | 8,606 |
| # of sequences tested in vitro | 45 (4.1%) | 20 (0.7%) | – |
| # of sequences with activity | 18 | 9 | – |
| # of sequences selected for development | 9 | 7 | – |
Timeline & Funds
1 year
Proof of Concept
NCI SBIR/STTR
Phase I
$400K
2 years
Preclinical Studies
NCI SBIR/STTR
Phase II
$2.25M
1-2 years
Clinical Trials Phase I/IIa
Investors
$2M-$3M
1-2 years
Clinical Trials Phase IIb
Investors/Partners
$4M-$6M